

Vaccines Summit Ohio

(VSOHIO21)

March 1-3, 2021 09:00 EDT

Conference Topics

Infectious & Non-Infectious Diseases

Vaccine Hesitency

Influenza Vaccines/Virus

Cancer Vaccines

Passive Vaccines

Clinical Trials

Technologies, Bioprocessing & Manufacturing

Therapeutic Vaccination

New Vaccine Development

DNA Vaccines

Emerging and Re-emerging Diseases

Vaccines Against Respiratory Pathogens

Biodenfense Vaccines

Immunotherapy & Immunodominance

Bacterial Vaccines

Vaccine Regulation

Make sure you are at the forefront of the vaccines industry. No matter where your interest lies, we have content, networking and potential partners for you

DAY 1

Keynote Session

09:00-09:10 **Opening Ceremony: Mahin Khatami**

09:10-09:40 Mahin Khatami

National Cancer Institute

Title: Vaccines And Drugs (Power Without) Weaken Bioenergetics And Immune Neuroplasticity (Power Within) And Induce Diseases

09:40-10:10 Casey Orvin

President, Society for Clinical Research Sites

Title: The Site Landscape: Gain Insight Into Site Trends And Metrics From The Site Community

10:10-10:40 Peter Nara

Chief Scientific Officer, Keystone Bio

Title: Decoding Immune Evading Mechanisms Of Pathogen's: Re-ordering Of Immuno-Dominance For Improved Immunity

10:40-11:10 Kevin Killeen

Chief Scientific Officer, Matrivax

Title: MVX01: A Serotype-Independent Pneumococcal Protein Fusion Vaccine Candidate

BREAK 10 MINUTES (11:10-11:20)

11:20-11:50 Yehuda Shoenfeld

Professor, Sheba Medical Center

Title: Vaccine and Autoimmunity

11:50-12:20 Geert Vanden Bossche

Founder & CSO, Coimeva LLC

Title: Can 'Modern' Vaccine Technologies Enable Pandemic Preparedness And Live Up To The Target Product Profile Of Global Health Vaccines?

12:20-12:50 Farshad Guirakhoo

Chief Scientific Officer, COVAXX & VAXXINITY

Title: UB612- The First Multitope Covid-19 Vaccine Entering Ph2 Trials

BREAK 30 MINUTES (12:50-13:20)

13:20-13:50 Andrew Lees

Scientific Director & Owner, Fina BioSolutions LLC

Title: Development of EcoCRM® CRM197 Carrier Protein

13:50-14:20 Jacob Glanville

Founder, CEO & President, Centivax Inc

Title: Provoking Spectrum Immune Responses Through Concentration-Conservation Coupling

Session: Viral Vaccines

- 14:20-14:35** Alexander Bukreyev
Professor, Departments of Pathology and Microbiology & Immunology, University of Texas Medical Branch
Title: The mRNA-1273 Vaccine Efficacy In A Severe COVID-19 Model: Attenuated Activation Of Pulmonary Immune Cells After The Challenge
- 14:35-14:50** Chinmay Jani
Mount Auburn Hospital, Harvard Medical School
Title: COVID-19 Vaccine Associated Takotsubo Cardiomyopathy
- 14:50-15:05** Sabine Hauck
Vice President R&D, Leukocare AG
Title: Effective Stabilization Of Viral Vaccines And Viral Vector Formulations Using An Algorithm Based Development Approach

BREAK 25 MINUTES (15:05-15:30)

Session: Animal Models & Clinical Development

- 15:30-15:45** Magdalena Tary-Lehmann
Chief Scientific Officer, Cellular Technology Limited
Title: Immunogenicity Assessment In Support Of Vaccine Therapy Programs- Use of ELISPOT
- 15:45-16:00** Alycia Fratzke
Department of Microbial Pathogenesis and Immunology, Texas A&M University
Title: Evaluation Of Vaccines Against The Zoonotic Illness, Q Fever, In Animal Models

DAY 2

Session: Immuno Oncology

- 09:00-09:30** Mahin Khatami (Keynote Talk)
National Cancer Institute
Title: Immune And Bioenergetics Of Cancer, Drugs And Vaccines: Future Outlooks
- 09:30-09:45** Giulio Tarro
Foundation T. & L. de Beaumont Bonelli for Cancer Research
Title: From Polio Vaccines To Oncogenic Viruses
- 09:45-10:00** Arabinda Chaudhuri
Indian Institute of Science Education and Research
Title: A Powerful Combination Approach For Combating Cancer Using In-vivo Dendritic Cell Targeted DNA Vaccination
- 10:00-10:15** Christof Plothe
Praxis für Osteopathie, Germany
Title: The Roots Of Health And Potential Lifelong Consequences Of Early Interventions Considerations For The Development Of Future Medicine And Suggestions For Diagnosis And Treatment

BREAK 15 MINUTES (10:15-10:30)

- 10:30-10:45** Pravin Kaumaya
Director, Vaccine Research, The Ohio State University
Title: Combination Of Cancer Vaccines And Immuno-Oncology Strategies
- 10:45-11:00** Robert O. Dillman
Chief Medical Officer, AIVITA Biomedical, Inc.
Title: Human Trials Testing Patient-Specific Therapeutic Vaccines: Dendritic Cells Loaded With Antigens From Autologous Cancer Initiating Cells

Session: Bacterial Vaccine

- 11:00-11:15** Mariagrazia Pizza
Senior Scientific Director, GSK Vaccines
Title: The 4CMenB Vaccine: From The Design To Real World Data
- 11:15-11:30** Larry S. McDaniel
Professor & Chair, Department of Microbiology & Immunology, University of Mississippi Medical Center
Title: Pneumococcal Vaccines And Changing Pneumococcal Ecology
- 11:30-11:45** Isis Kanevsky
Director, Pfizer Vaccine
Title: Advances In Bacterial Vaccine Development
- 11:45-12:00** Tobias Kaeser
Assistant Professor in Swine Immunology, North Carolina State University
Title: Chlamydia suis Pre-Exposed Outbred Pigs As A Novel Biomedical Animal Model For Chlamydia trachomatis Vaccine Development

BREAK 30 MINUTES (12:00-12:30)

- 12:30-12:45** Matthew Coleman
Adjunct Professor, Department of Radiation Oncology, University of California, Davis
Title: Developing A NanoScaffold-Based Chlamydia trachomatis Vaccine
- 12:45-13:00** Rebecca Ingram
Senior Lecturer in Infection and Immunity, Queen's University Belfast
Title: Innate Lymphoid Cell Memory Protects Against Bacterial Infection
- 13:00-13:15** David E. Briles
Professor Emeritus, The University of Alabama at Birmingham
Title: Polysaccharide-Conjugate Vaccines Are Not Able To Adequately Control Pneumococcal Meningitis
- 13:15-13:30** Xuefei Huang
Professor of Biomedical Engineering, Michigan State University
Title: Development Of Carbohydrate Based Anti-Microbial Vaccines

BREAK 15 MINUTES (13:30-13:45)

Session: Influenza, RSV & TB

- 13:45-14:00** Martha A. Alexander-Miller
Director Center for Vaccines at the Extremes of Aging, Wake Forest School of Medicine
Title: Development Of A Safe And Efficacious Vaccine Against Influenza For Use In Newborns
- 14:00-14:15** Marie Mazur
Vaccine Consultant & Strategic Advisor, Director at Ready2Respond
Title: Ready2Respond: A Unique Collaboration Created To Enhance The World Readiness To The Next Pandemic
- 14:15-14:30** Sarah Ives
Co-founder, Centivax Inc
Title: Computational Immunology Enables Broad-Spectrum Vaccines
- 14:30-14:45** Jon Heinrichs
Associate Vice President, New Products Portfolio Franchise Lead, Sanofi Pasteur
Title: Prevention Of RSV In Children

DAY 3

Session: New Vaccine Development

- 09:00-09:15** S. Louise Cosby
Head of Virology Branch, Agri-Food and Biosciences Institute
Title: New Veterinary Mucosal Vaccine Development And Challenge Models
- 09:15-09:30** Kunihiro Yamashita
Medical Device Division, Innovation & Business Development Headquarters, Daicel Corporation, Tokyo
Title: Comparison Of Gene Expression And Immune-Response By Pyro-Drive Jet Injector (PJI) And Electroporation
- 09:30-09:45** Vjollca Konjufca
Southern Illinois University
Title: Induction Of Immunity In The Female Reproductive Tract By Per-Oral Antigen Administration
- 09:45-10:00** Anamika Basu
Department of Biochemistry, Gurudas College
Title: Strategies For Vaccine Design For Corona Virus Using Immunoinformatics Technique
- 10:00-10:15** Tom Lake
SVP, Vaccine Alliances & Commercialization, Vaxxas
Title: Acceptability & Usability Of A Microarray Patch For Skin Delivery Of Vaccines
- 10:15-10:30** Gavin Wright
Senior Group Leader, Wellcome Sanger Institute
Title: An Invariant Trypanosoma vivax Vaccine Antigen Inducing Protective Immunity

BREAK 15 MINUTES (10:30-10:45)

- 10:45-11:00** Robert DeWitte
Co-founder & CEO, Elarex Inc
Title: Recent Advances In Stabilizing Biologicals And Vaccines
- 11:00-11:15** Gordon Irvine
Formulation Inc
Title: Vaccine Formulation Optimization Using Static Multiple Light Scattering Technology
- 11:15-11:30** Li Shi
Chief Scientific Advisor (CSA), Zerun Bio
Title: Development Of VLP Based EV71 Vaccine
- 11:30-11:45** Ritu Chakravarti
Assistant Professor, University of Toledo
Title: Prophylactic Vaccine For Rheumatoid Arthritis
- 11:45-12:00** Edward Fogarty
Affiliation
Title: New Vaccine Development

BREAK 30 MINUTES (12:00-12:30)

Session: Emerging Diseases

- 12:30-12:45** Subhash C. Basak
Department of Chemistry and Biochemistry, University of Minnesota
Title: Computer-Aided New Approach In The Surveillance And Peptide Vaccine Design For Emerging Global Pathogens Like Zika And Covid-19
- 12:45-13:00** Michael Har-Noy
Founder & Acting Chairman, Immunovative Therapies
Title: Allo-Priming As A Universal Anti-Viral Vaccine: Protecting Elderly From Current COVID-19 And Any Future Unknown Viral Outbreak
- 13:00-13:15** Pirouz Daftarian
Senior Manager, Applications, Immuno-Oncology & Vaccines, JSR Life Sciences
Title: SARS-CoV-2 Specific CD4+ T Cells In Convalescent Host, A Potential Surrogate Of Prolonged Immunity
- 13:15-13:30** Raymond Obomsawin
Senior Research Consultant & Advisor, Kina Consulting International
Title: Emerging Diseases

BREAK 30 MINUTES (13:30-14:00)

Session: Vaccine Hesitancy & Safety

- 14:00-14:15** Tsurriel Rashi
School Of Communication, Ariel University
Title: Jewish Ethics Regarding Vaccination
- 14:15-14:30** Tilahun Yilma
Professor, University of California Davis
Title: Strategies For Enhancing The Safety And Efficacy Of Live Recombinant Vaccines

MEET YOU NEXT AT VACCINES SUMMIT BOSTON 2021